Kinnate Biopharma Inc. announced the appointment of Richard Williams as Chief Medical Officer. Most recently Chief Medical Officer and Global Head of Oncology Programs at WuXi NextCODE, Williams brings to Kinnate more than a decade of global clinical strategy and drug development experience in the biopharmaceutical industry. The company has also announced the appointment of Robert Kania, as Senior Vice President, Drug Discovery. While at WuXi NextCODE, Williams was responsible for leading the clinical development of large-scale genomics and target biomarker discovery programs. Previously, he was with cancer detection company GRAIL as Group Medical Director and Program Lead of the Circulating Cell-Free Genome Atlas. He also guided the development of early clinical oncology assets as Head of Early Development Oncology Group and Early Development Leader at Amgen. While Senior Medical Director at Puma Biotechnology.